Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
SEATTLE, Jan. 27, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City.
Brad Gray, President and Chief Executive Officer, is scheduled to present on Wednesday, February 10, 2016 at 1:50pm ET. Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
